Compare Eli Lilly And Co (LLY) vs Oscar Health Inc (OSCR) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Oscar Health (OSCR) trades at $29.60, up 1.72% today, showing mixed signals with a bullish technical trend but bearish oscillators. The company reported revenue growth to $11.70B in 2025, though net income remains negative at -$443.15M. Recent earnings beat expectations in Q1 2026 with EPS of $2.07, while analyst sentiment is divided with a consensus price target of $24.67. Positive cash flow trends and media coverage highlight growth potential amid ongoing profitability challenges.

Outlook: OSCR offers growth exposure in health insurance with strong revenue expansion and cash flow, but profitability risks persist. Investment opportunity lies in execution toward breakeven, while risks include margin pressure and competitive threats. The stock's current price above consensus target suggests cautious optimism is warranted.